Alpha-MSH is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2026-03-13. Numbers and descriptions here follow the published literature rather than marketing material.
Melanotan II binds several melanocortin receptor subtypes rather than a single target. MC1R on melanocytes drives melanin synthesis, while MC3R and MC4R participate in energy balance, appetite, and sexual response pathways. This lack of selectivity explains why reported effects extend beyond skin darkening. Substitutions at positions four and seven, including norleucine and D-phenylalanine, increase potency and resistance to peptidases. Understanding which receptor mediates which effect remains an active area of investigation.
Published human data come mostly from small, short studies rather than large controlled trials. Reported outcomes include increased skin pigmentation and, in some reports, effects on appetite and libido, but sample sizes are small and follow-up is limited. Whether long-term use produces durable pigment changes or adverse effects is not established. Because products sold outside pharmacies are not standardized, the actual content of any given vial is often unknown. Independent testing of such material is uncommon.
Melanotan II is a synthetic cyclic heptapeptide analog derived from the core sequence of alpha-melanocyte-stimulating hormone. Researchers at the University of Arizona synthesized it during the 1980s while studying pigmentation and appetite signaling. The compound is not an approved medicine in any major jurisdiction and appears mainly in laboratory and research-chemical settings. Its structure incorporates a lactam bridge between side chains, which constrains the ring and slows enzymatic breakdown relative to the natural hormone.
Regulatory treatment varies between countries. Several national medicines agencies have classified the peptide as unapproved, and customs authorities in some jurisdictions seize shipments on that basis. A few jurisdictions channel supply through prescription-only frameworks that do not list the substance by name. Because the material circulates mainly through online vendors, composition and purity are rarely verified before sale. Surveys of unapproved peptide products have reported labels that did not match measured content in a substantial fraction of samples.
Melanotan II is a synthetic cyclic heptapeptide analogue of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation signalling. Its structure substitutes a lactam bridge between side chains to increase stability relative to the native hormone. The compound is also known by the shorthand MT-II and by several non-proprietary synonyms used in research catalogues. It is not an approved therapeutic product in any major jurisdiction; material sold under this name is typically offered as a laboratory reagent rather than as a medicine.
Activity is attributed to agonism at melanocortin receptors, particularly MC1R and MC4R. Activation of MC1R on melanocytes increases melanin synthesis, which underlies the reported tanning effect. MC4R engagement in the central nervous system is linked to appetite suppression and to effects on sexual arousal reported in early clinical studies. Those studies were small and were not designed to establish efficacy or long-term safety. Receptor selectivity among the melanocortin subtypes is not absolute, which complicates attribution of any effect to a single pathway.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic cyclic heptapeptide | Analog of alpha-melanocyte-stimulating hormone |
| Primary receptor family | Melanocortin receptors MC1R through MC5R | Binding is not subtype-selective |
| Development period | 1980s | Synthesized during pigmentation and appetite research |
| Regulatory status | Not an approved medicine | No major regulator has authorized human use |
| Related compound | Afamelanotide | Linear analog studied for photoprotection |
The peptide acts as a non-selective agonist at melanocortin receptors, showing affinity for MC1R, MC3R, MC4R and MC5R. Activation of MC1R on melanocytes drives the conversion of tyrosine into melanin and shifts production toward the darker eumelanin form. MC4R signalling in the central nervous system is linked to appetite and energy balance, which helps explain why reduced food intake appeared in early human studies. Effects on MC4R and on vascular tone also account for the erectile responses recorded as unexpected findings in those same trials.
Melanotan-2 is frequently confused with afamelanotide, a linear analogue authorised in the European Union for erythropoietic protoporphyria. The two compounds differ in chain length, ring structure and receptor selectivity, so findings for one cannot be transferred directly to the other. Published controlled human data on melanotan-2 remain sparse, and much of what circulates online derives from small studies or unpublished reports. Questions about effect size, dose-response behaviour and long-term safety therefore remain unresolved.
== Structural studies == As of late 2007, 11 structures have been solved for this class of enzymes, with PDB accession codes PDB: 1WXE, PDB: 1WXF, PDB: 1WXG, PDB: 1WXH, PDB: 1WXI, PDB: 1XNG, PDB: 1XNH, PDB: 2E18, PDB: 2PZ8, PDB: 2PZA, and PDB: 2PZB.
=== Former commissioners === David Gallop was the initial chief executive officer of the restructured ARL Commission. He was previously the CEO of the NRL and his contract extension to become inaugural ARL CEO was a condition placed by News Limited with the ARL. On 5 June 2012 the ARL announced Gallop's departure from the CEO position and that he would take up a position at the FFA in 2013. David Smith was announced as the new ARL CEO in November 2012, taking charge on 1 February 2013.
=== Businesses === Air Link, New South Wales, Australia Hong Kong Link, toll tunnels and bridges company Link REIT, Hong Kong real estate investment trust The Link (retailer), UK mobile phone retailer Link Aviation Devices, a manufacturer of aircraft simulator, now a subsidiary of L3 Technologies
Military submarines first made a significant impact in World War I. Forces such as the U-boats of Germany saw action in the First Battle of the Atlantic, and were responsible for sinking RMS Lusitania, which was sunk as a result of unrestricted submarine warfare and is often cited among the reasons for the entry of the United States into the war. At the outbreak of the war, Germany had only twenty submarines available for combat, although these included vessels of the diesel-engined U-19 class, which had a sufficient range of 5,000 miles (8,000 km) and speed of 8 knots (15 km/h) to allow them to operate effectively around the entire British coast. By contrast, the Royal Navy had a total of 74 submarines, though of mixed effectiveness. In August 1914, a flotilla of ten U-boats sailed from their base in Heligoland to attack Royal Navy warships in the North Sea in the first submarine war patrol in history. The U-boats' ability to function as practical war machines relied on new tactics, their numbers, and submarine technologies such as combination diesel–electric power system developed in the preceding years. More submersibles than true submarines, U-boats operated primarily on the surface using regular engines, submerging occasionally to attack under battery power. They were roughly triangular in cross-section, with a distinct keel to control rolling while surfaced, and a distinct bow. During World War I more than 5,000 Allied ships were sunk by U-boats. The British responded to the German developments in submarine technology with the creation of the K-class submarines.
Nycomed, a Swiss drug company which manufactures Actovegin, claims it can be used for circulation and nutrition disturbances, skin grafting, burns, and wound-healing impairment. Actovegin has also been used as a performance enhancer. It has been investigated for use in treatment of polyneuropathy in diabetes, and for stroke. One study found that when tissues suffer from hypoxia caused circulation abnormalities, Actovegin helps capillaries improve circulation by enhancing the neogenic mechanism in blood vessels. Anaphylactic shock has been observed in at least one patient treated with actovegin. There are reports suggesting that Actovegin have ergogenic ability, however one small trial found no apparent benefit from short-term use. Two studies certified Actovegin to have an anti-inflammatory effect. One of the two studies certified Actovegin to reduce Progressive muscular atrophy-induced inflammation in human cells. Another study certified Actovegin to have a positive impact on the growth of muscle cells.
Sources: en.wikipedia.org
oil/fat {\displaystyle {{\textrm {W}}_{\textrm {oil/fat}}}} is the weight of sample, in g. For example, standard methods for determination of SV of vegetable and animal fats are as follows: The SV can also be calculated from the fatty acid composition as determined by gas chromatography (AOCS Cd 3a-94). Handmade soap makers who aim for bar soap use sodium hydroxide (NaOH), commonly known as lye, rather than KOH (caustic potash) which produces soft paste, gel or liquid soaps. In order to calculate the lye amount needed to make bar soap, KOH values of SV can be converted to NaOH values by dividing KOH values by the ratio of the molecular weights of KOH and NaOH (1.403). The theoretical SV of a pure triglyceride molecule can be calculated by the following equation (where MW is its molecular weight):
The medical historian Christoph Gradmann has reconstructed Koch's beliefs regarding the function of tuberculin: the medicine did not kill the bacteria but rather initiated a necrosis of the tubercular tissue, thus "starving" the tuberculosis pathogen. This idea was then outside customary medical theories, as it remains today. The tuberculin scandal was understood as a cautionary tale in regards to testing medicine. Emil von Behring's introduction of his diphtheria antitoxin in 1893 had been preceded by lengthy clinical testing, and the serum was only slowly introduced into practical use, accompanied by a critical discussion among qualified experts. Paul Ehrlich also proceeded with conspicuous caution in 1909 when introducing the first synthetically produced chemotherapeutic agent, Salvarsan, as a cure for an infectious disease, syphilis.
Protomastigineae, in which absorption of food-particles in holozoic nutrition occurs at a localised point of the cell surface, often at a cytostome, although many groups were merely saprophytes; it included the majority of colourless flagellates, and even many "apochlorotic" algae; Pantostomatineae (or Rhizomastigineae), in which the absorption takes place at any point on the cell surface; roughly corresponds to "amoeboflagellates"; Distomatineae, a group of binucleate "double individuals" with symmetrically distributed flagella and, in many species, two symmetrical mouths; roughly corresponds to current Diplomonadida. Presently, these groups are known to be highly polyphyletic. In modern classifications of the protists, the principal flagellated taxa are placed in the following eukaryote groups, which include also non-flagellated forms (where "A", "F", "P" and "S" stands for autotrophic, free-living heterotrophic, parasitic and symbiotic, respectively):
==== Transistors ==== Bismuth-based materials have been claimed to enable smaller, faster, and more energy-efficient transistors than traditional silicon. Bismuth offers a small bandgap and high electron mobility. It has topological insulator states, conducting along its surface/edges while still insulating internally. Two-dimensional semiconductor (2D) materials can be produced from it, enabling thinner and higher-performance devices. Such 2D bismuth materials support subnanometer channel lengths, surpassing silicon's practical limits. However, bismuth's anisotropic heat transport can complicate chip design. Bismuth telluride (Bi2Te3) has been investigated for use in thermoelectric transistors that use temperature gradients (e.g., via laser illumination) to generate electricity, yielding 0.7093 μW in experimental setups. They operate by leveraging the Seebeck effect, using a temperature difference to drive charge carrier movement. Bismuth oxyselenides (Bi2O2Se and Bi2SeO5) have been investigated for use in field-effect transistors (FETs). These 2D materials exhibit high electron mobility (e.g., 10–15 cm2/(V·s)) and stability in air. One study reported that these materials enabled transistors that were 40% faster and 10% more efficient than Intel's 3 nm chips. Bismuth can reduce contact resistance when paired with 2D semiconductors such as MoS2. This eliminates the Schottky barrier—a common efficiency issue in metal-semiconductor interfaces.
Sources: en.wikipedia.org
No regulator in a major market has approved it for human use. It appears in research settings and in products marketed outside pharmacy channels. Legal status for personal possession varies by country.
Afamelanotide is a linear analog that has received approval in some jurisdictions for a specific photoprotection indication. Melanotan II is cyclic and less selective across melanocortin receptors. The two are related but are not interchangeable in regulatory or clinical terms.
A compound that activates several receptor subtypes may produce effects beyond pigmentation. Selectivity influences which tissues respond and shapes the side-effect profile described in reports. Designing subtype-selective analogs is a stated goal of melanocortin research.
No. No major regulatory agency has granted a marketing authorisation for melanotan II as a medicine. Products sold under this name are generally presented as laboratory reagents and are not subject to the batch-release testing applied to approved drugs.